OIL & GAS: LATEST INTERVIEWS MORE INTERVIEWS
"Remote projects may prefer to isolate and limit the number of external individuals visiting as a precaution to avoid the virus spreading, but they need to maintain their supply chain so drones are a perfect unmanned logistics solution."
Deloitte Gabon explains the current regulatory environment for the country’s oil and gas industry.
Octomar explains how the company has navigated this difficult year and its plans to expand to partake in Mozambique’s exciting offshore developments.
Acrep Angola E&P analyses the difficulties of expanding in Angola during the pandemic and with lower oil prices.
OIL & GAS: LATEST ARTICLES
The State of Gabon’s Oil Industry
September 09, 2020
Gabon’s maturing fields and decreasing production levels, together with the low price regime over the past five years, have brought the country’s oil industry to a turning point.
2020: Nigeria - The Year of Natural Gas
August 11, 2020
Nigeria has enormous potential to diversify the economy away from crude oil, which has overshadowed the gas in Nigeria’s oil and gas industry. The country is struggling to exploit its natural gas resources which rank among the 10 largest worldwide.”
OIL & GAS: RECENTLY RELEASED PUBLICATIONS
MACIG
SPANISH
SUBSCRIBE TO OUR NEWSLETTER
RECENTLY PUBLISHED
United States Life Sciences 2023
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
In many ways, 2022 was a turning point for the US life sciences industry. After having provided a lightning-quick response to the Covid-19 pandemic, the industry gathered the lessons learned and sought a sense of normalcy to continue developing necessary drugs for patients worldwide. Yet, the geopolitical, macroeconomic, and regulatory environments all come with their set of challenges, forcing executives into increasingly complex decisions when defining their strategies.
PARTNER EVENTS
SUBSCRIBE TO OUR
NEWSLETTER
- Get GBR content delivered to your inbox
- Receive industry based news
- Completely free, e-mail only
